Integrin VLA-5 Negative Primary Plasma Cell Leukemia.

Ohtake, Ken‐Ichi; Takeuchi, Tsutomu; Saito, Keiko; Itô, Tatsuya; Ito, Isao; Aoki, Kazutoshi; Takano, Yasuhide; Amano, Koichi; Hosono, Osamu; Koide, Jun; Suzuki, Hiroshi; Abe, Tohru

doi:10.2169/internalmedicine.32.565

Cited by 6 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42 Extramedullary MM or PCL is also associated with loss of very late antigen-5 (VLA-5), 39,43 LFA-3, 37,44 and tetraspanin proteins, such as CD9 and CD82, which are cell surface molecules involved in adhesion, motility, and invasion. 6,45 Down-regulation of chemokine receptors, such as CXCR4 on tumor cells, may also lead to impaired retention of PCL in the BM.…”

Section: Adhesion Molecules and Chemokine Receptorsmentioning

confidence: 99%

How I treat plasma cell leukemia

Donk

Lokhorst

Anderson

et al. 2012

Blood

122

106

View full text Add to dashboard Cite

Section: Adhesion Molecules and Chemokine Receptorsmentioning

confidence: 99%

How I treat plasma cell leukemia

Donk

Lokhorst

Anderson

et al. 2012

Blood

122

106

View full text Add to dashboard Cite

“…Opinions on the role of late activation antigens in PCL are divided. Some authors have observed the expression of all these molecules on leukemic cells, while others have found the presence of VLA-4 combined with an absence of VLA-5 expression and stated that this surface antigen constellation was important for leukemic proliferation [45,46]. The expression of VLA-4 on the leukemic cells is a requisite of their increased invasiveness because contact between this antigen and its ligand in a capillar wall leads into extravasation of those cells from the blood into extravascular space [47].…”

Section: Discussionmentioning

confidence: 99%

Flow cytometric immunophenotypic characteristics of plasma cell leukemia

Kraj¹,

Kopeć-Szlężak²,

Pogłód³

et al. 2011

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:The aim of this prospective study was to define the flow cytometric characteristics of simultaneously investigated bone marrow and peripheral blood plasma cells antigens expression in 36 plasma cell leukemia (PCL) patients. The immunophenotypic profile of plasma cells was determined with a panel of monoclonal antibodies. The antigen expression intensity was calculated as relative fluorescence intensity (RFI). Bone marrow plasma cells showed expression of particular antigens in the following proportion of cases: CD49d 100%, CD29 94%, CD54 93%, CD44 83%, CD56 60%, CD18 26%, CD11b 29%, CD11a 19%, CD117 27%, CD71 30%, CD126 100% and CD19 0%, while the expression of those antigens on peripheral blood plasma cells was present in the following percentage of patients: CD49d 100%, CD29 96%, CD54 93%, CD44 95%, CD56 56%, CD18 50%, CD11b 53%, CD11a 29%, CD117 26%, CD71 28%, CD126 100% and CD19 0%. The expression of CD54 was significantly higher than that of adhesion molecules belonging to the integrin b2 family: CD11a, CD18 and CD11b, on both bone marrow and peripheral blood cells (p < 0.01). Expression of CD18, CD11a and CD11b was differential between two cell compartments: lower on bone marrow and higher on peripheral blood cells. We found that plasma cells in the bone marrow of patients with plasma cell leukaemia showed significantly greater granularity and size than those in the peripheral blood (p = 0.0001 and p = 0.04, respectively). However, no differences in cell size or granularity were revealed between bone marrow plasma cells from patients with PCL and multiple myeloma. In conclusion, impaired expression of adhesion molecules such as CD11a/CD18 (LFA-1) or CD56 may explain hematogenic dissemination characterizing PCL. The following pattern of adhesion molecule expression according to the proportion of plasma cells expressing a given antigen in peripheral blood and bone marrow and arranged in diminishing order may be established: CD49d > CD44 > CD54 > CD29 > CD56 > CD18 > CD11b > CD11a. Immuno-phenotyping of plasma cells in PCL, as in multiple myeloma, might be useful in detecting minimal residual disease in cases with aberrant antigen expression and for selecting therapeutic agents towards specific membrane targets.

show abstract

“…It is associated with a poor prognosis, with a mean survival of less than 8 months [47] and a 5-year survival of 13% [3]. PCL is frequently the initial presentation of a plasma cell dyscrasia [49][50][51][52][53] or it may occur many years into the disease [54][55][56]. Our patient had a few peripheral blood plasma cells on presentation, which disappeared with successful treatment of his myeloma, but terminally he had a leukemic picture, with progression from 4 to 28% (4,000/l) peripheral blood plasma cells over 9 days.…”

Section: Discussionmentioning

confidence: 99%

Multiple myeloma: A patient with unusual features including intracranial and meningeal involvement, testicular involvement, organomegaly, and plasma cell leukemia

1998

View full text Add to dashboard Cite

A 27-year-old Chinese male presented with multiple myeloma. Over his 18-month course he manifested a number of unusual features of his disease including his young age, marked organomegaly, a testicular plasmacytoma, multiple intracranial extraskeletal plasmacytomas and meningeal involvement, and peripheral blood plasmacytosis. The case is described and recent literature on these rare manifestations is reviewed. Am. J. Hematol. 57:51-56, 1998.

show abstract

Integrin VLA-5 Negative Primary Plasma Cell Leukemia.

Cited by 6 publications

References 11 publications

How I treat plasma cell leukemia

How I treat plasma cell leukemia

Flow cytometric immunophenotypic characteristics of plasma cell leukemia

Multiple myeloma: A patient with unusual features including intracranial and meningeal involvement, testicular involvement, organomegaly, and plasma cell leukemia

Contact Info

Product

Resources

About